Tremblay CS & Curtis DJ (2014) The clonal evolution of leukemic stem cells in T-cell acute lymphoblastic leukemia. Curr Opin Hematol 21, 320–325.
Pancewicz J & Nicot C (2011) Current views on the role of Notch signaling and the pathogenesis of human leukemia. BMC Cancer 11, 502.
Tzoneva G & Ferrando AA (2012) Recent advances on NOTCH signaling in T-ALL. Curr Top Microbiol Immunol 360, 163–182.
Raivio KO & Andersson LC (1982) Glutamine requirements for purine metabolism in leukemic lymphoblasts. Leuk Res 6, 111–115.
Kitoh T, Kubota M, Takimoto T, Hashimoto H, Shimizu T, Sano H, Akiyama Y & Mikawa H (1990) Metabolic basis for differential glutamine requirements of human leukemia cell lines. J Cell Physiol 143, 150–153.
Villar VH, Merhi F, Djavaheri-Mergny M & Durán RV (2015) Glutaminolysis and autophagy in cancer. Autophagy 11, 1198–1208.
Durán RV, Oppliger W, Robitaille AM, Heiserich L, Skendaj R, Gottlieb E & Hall MN (2012) Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell 47, 349–358.
Durán RV, MacKenzie ED, Boulahbel H, Frezza C, Heiserich L, Tardito S, Bussolati O, Rocha S, Hall Mn & Gottlieb E (2013) HIF-independent role of prolyl hydroxylases in the cellular response to amino acids. Oncogene 32, 4549–4556.
Tardito S, Oudin A, Ahmed SU, Fack F, Keunen O, Zheng L, Miletic H, Sakariassen PØ, Weinstock A, Wagner A et al. (2015) Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat Cell Biol 17, 1556–1568.
Herranz D, Ambesi-Impiombato A, Sudderth J, Sánchez-Martín M, Belver L, Tosello V, Xu L, Wendorff AA, Castillo M, Haydu JE et al. (2015) Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nat Med 21, 1182–1189.
Kahlert UD, Cheng M, Koch K, Marchionni L, Fan X, Raabe EH, Maciaczyk J, Glunde K & Eberhart CG (2016) Alterations in cellular metabolome after pharmacological inhibition of Notch in glioblastoma cells. Int J Cancer 138, 1246–1255.
Basak NP, Roy A & Banerjee S (2014) Alteration of mitochondrial proteome due to activation of Notch1 signaling pathway. J Biol Chem 289, 7320–7334.
Iggo R & Richard E (2015) Lentiviral transduction of mammary epithelial cells. Methods Mol Biol 1293, 137–160.
De Keersmaecker K, Lahortiga I, Mentens N, Folens C, Van Neste L, Bekaert S, Vandenberghe P, Odero MD, Marynen P & Cools J (2008) In vitro validation of γ-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. Haematologica 93, 533–542.
Villar VH, Nguyen TL, Delcroix V, Terés S, Bouchecareilh M, Salin B, Bodineau C, Vacher P, Priault M, Soubeyran P et al. (2017) mTORC1 inhibition in cancer cells protects from glutaminolysis-mediated apoptosis during nutrient limitation. Nat Commun 8, 14124.
Villar VH & Durán RV (2017) Glutamoptosis: a new cell death mechanism inhibited by autophagy during nutritional imbalance. Autophagy 13, 1078–1079.
Van Nguyen T, Lee JE, Sweredoski MJ, Yang S-J, Jeon S-J, Harrison JS, Yim J-H, Lee SG, Handa H, Kuhlman B et al. (2016) Glutamine triggers acetylation-dependent degradation of glutamine synthetase via the thalidomide receptor cereblon. Mol Cell 61, 809–820.
Tan HWS, Sim AYL & Long YC (2017) Glutamine metabolism regulates autophagy-dependent mTORC1 reactivation during amino acid starvation. Nat Commun 8, 338.
Saxton RA & Sabatini DM (2017) mTOR signaling in growth, metabolism, and disease. Cell 169, 361–371.
Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT & Aster JC (2004) Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269–271.
Purow BW, Haque RM, Noel MW, Su Q, Burdick MJ, Lee J, Sundaresan T, Pastorino S, Park JK, Mikolaenko I et al. (2005) Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 65, 2353–2363.
Sikandar SS, Pate KT, Anderson S, Dizon D, Edwards RA, Waterman ML & Lipkin SM (2010) NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res 70, 1469–1478.
Petronini PG, Urbani S, Alfieri R, Borghetti AF & Guidotti GG (1996) Cell susceptibility to apoptosis by glutamine deprivation and rescue: survival and apoptotic death in cultured lymphoma-leukemia cell lines. J Cell Physiol 169, 175–185.
Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M et al. (2010) Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 107, 8788–8793.
Abu Aboud O, Habib SL, Trott J, Stewart B, Liang S, Chaudhari AJ, Sutcliffe J & Weiss RH (2017) Glutamine addiction in kidney cancer suppresses oxidative stress and can be exploited for real-time imaging. Cancer Res 77, 6746–6758.
Distasio JA, Salazar AM, Nadji M & Durden DL (1982) Glutaminase-free asparaginase from vibrio succinogenes: an antilymphoma enzyme lacking hepatotoxicity. Int J Cancer 30, 343–347.
Villa P, Corada M & Bartosek I (1986) L-asparaginase effects on inhibition of protein synthesis and lowering of the glutamine content in cultured rat hepatocytes. Toxicol Lett 32, 235–241.
Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon PS et al. (2002) A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood 99, 1986–1994.
